New Antibiotic Shows Superior Results Against Drug-Resistant Gram-Negative Infections
In a major development for the treatment of antibiotic-resistant infections in India, the Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorization to Wockhardt’s breakthrough antibiotic ZAYNICH® (Zidebactam/Cefepime). The approval represents a significant step forward in addressing the growing challenge of antimicrobial resistance (AMR), particularly for difficult-to-treat Gram-negative bacterial infections.
Approved for Complicated Urinary Tract Infections
ZAYNICH® has been approved for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis (a severe kidney infection), as well as cases involving concurrent Gram-negative bacteremia, where bacteria spread into the bloodstream.
Complicated urinary tract infections are often associated with higher treatment failure rates due to increasing bacterial resistance to conventional antibiotics, making the availability of new treatment options critically important.
Phase 3 Trial Demonstrated Superior Efficacy
The CDSCO approval is based on positive results from the ENHANCE-1 Phase 3 clinical trial, a multinational, randomized, double-blind study designed to evaluate the safety and efficacy of ZAYNICH® compared with meropenem, one of the most commonly used last-resort antibiotics for severe bacterial infections.
The study enrolled patients suffering from complicated urinary tract infections and assessed treatment outcomes based on both clinical recovery and microbiological eradication.
Key Findings from the ENHANCE-1 Trial
- 89% of patients treated with ZAYNICH® achieved the primary endpoint.
- 68.4% of patients treated with meropenem achieved the same endpoint.
- ZAYNICH® demonstrated a treatment advantage of more than 20 percentage points over meropenem.
- Superior performance was observed in both clinical cure rates and microbiological eradication rates at the test-of-cure assessment.
These results indicate that ZAYNICH® may offer a more effective treatment option for serious Gram-negative bacterial infections, particularly in cases where resistance limits the effectiveness of existing therapies.
Addressing the Global Threat of Antimicrobial Resistance
Antimicrobial resistance has emerged as one of the most pressing public health challenges worldwide. Gram-negative bacteria, including organisms such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, are increasingly developing resistance to multiple antibiotic classes, making infections harder to treat and increasing the risk of complications and mortality.
The introduction of a novel antibiotic combination such as ZAYNICH® is expected to strengthen treatment options available to healthcare professionals managing severe resistant infections.
Significance for India’s Healthcare System
India carries a significant burden of antimicrobial resistance due to widespread antibiotic use and the growing prevalence of multidrug-resistant bacterial pathogens. The approval of ZAYNICH® provides clinicians with a new weapon against resistant Gram-negative infections and may help improve treatment outcomes for hospitalized patients.
Industry experts believe the launch of innovative antibiotics is essential to preserving the effectiveness of modern healthcare, particularly for patients requiring intensive care, major surgeries, organ transplants, and cancer treatments where infection control is critical.
Looking Ahead
With CDSCO approval now secured, Wockhardt is expected to make ZAYNICH® available for clinical use across India. The company views the approval as a major milestone in its efforts to develop innovative anti-infective therapies and combat the growing threat of drug-resistant bacteria.
As antimicrobial resistance continues to rise globally, the availability of advanced antibiotics like ZAYNICH® could play an important role in improving patient outcomes and safeguarding the future of infectious disease treatment.
Key Highlights
✔ CDSCO approves Wockhardt’s ZAYNICH® (Zidebactam/Cefepime)
✔ Indicated for complicated urinary tract infections (cUTI) and pyelonephritis
✔ Effective against difficult Gram-negative bacterial infections
✔ Phase 3 ENHANCE-1 trial showed superiority over meropenem
✔ Achieved 89% success rate versus 68.4% with meropenem
✔ Important advancement in combating antimicrobial resistance (AMR)
Category: Pharma News | Antibiotics | CDSCO Approval | Infectious Diseases | Healthcare Innovation
Company: Wockhardt
Drug: ZAYNICH
Recommended Products
